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for tumour size, grade and histological type, and 26% were node
positive on histology.
Sensitivity Specificity Concordance
Per node 96% 95% 95%
Per patient 96% 94% 95%
The sensitivity for macrometastases was 99.8%.
Conclusion: Our experience of the use of RT-PCR for intraoper-
ative analysis of sentinel lymph nodes shows a highly favourable
concordance with histological analysis. It offers the ability to pro-
ceed to immediate axillary clearance and is, therefore, beneficial
to patients. It is consistent and reliable. We believe intra-opera-
tive analysis should be available to all patients undergoing SLNB
as part of breast cancer surgery.
doi:10.1016/j.ejcsup.2010.06.060
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Background and aims: One-step nucleic acid amplification
(OSNA) is an assay of cytokeratin 19 mRNA for intraoperative
detection of lymph node metastasis in breast cancer. Patients
who havemicro-metastases proceed to level 1 axillary node clear-
ance (ANC) and those with macro-metastases or positive but
inhibited results to level 3 ANC, avoiding a second operation.
Presenceorabsenceofmicro-metastasis dependson theagreed
cut off point on the amplification curve. The aim of this study was
to review our data following introduction of OSNA and review the
outcome of ANC in patients with positive OSNA results.
Methods: Data were collected prospectively from the introduc-
tion of this technique to date (01/12/2008 to 06/05/2010). Opera-
tions have been performed by four consultant breast surgeons.
Results: Three hundred and ten patients had 641 nodes analysed
in the study period. 69% had wide local excision, 28% mastectomy
and 7% SNB alone. Thirty-four percent had positive sentinel nodes
and had further axillary surgery. Of these 39% had micro-metasta-
ses and61%hadmacro-metastases or positive but inhibited results.
Of the patients with micro-metastases 10% had further positive
non-sentinel nodes. 41.2% of the patients with macro-metastases
or positive but inhibited results had positive non sentinel nodes.
Conclusion: Over a third of patients had positive lymph nodes
detected with OSNA and underwent ANC, eliminating the need
for a second operation. Only 10% of patients with micro-metasta-
ses have further positive non-sentinel nodes. National trials are
underway to determine if axillary clearance should be considered
the correct option for this cohort of patients.
doi:10.1016/j.ejcsup.2010.06.061
O-61 ARGON BEAM COAGULATOR IN BREAST SURGERY: EFFECT
ON THE INCIDENCE OF BREAST SEROMA
V. Lefemine, W. Samra. Glan Clwyd Hospital, Rhyl, UK
Aim: To compare the incidence of breast seroma following
mastectomy, upon the use of argon beam coagulator (ABC) or con-
ventional monopolar diathermy (MD).
Method: Data were collected retrospectively from January 2006
to August 2008 for all patients undergoing a simple mastectomy.
Postoperative incidence of seroma, amount of drainage on day
of discharge and number of days from drain removal to seroma
formation were recorded.
Results: Fifty-six patients were studied, comparison were
made for those who underwent a simple mastectomy using
ABC (30 women) or MD (25 women). The two groups were similar
with regard to age, type of axillary surgery and operative time.
The incidence of postoperative breast seroma development was
30% in the former group and 36% in the latter. In the ABC group
a high postoperative drainage (>50 ml/24 h) on the day of drain
removal was associated with a higher incidence of seroma,
whereas this was not observed in the MD group.
Discussion: The ABC has been recommended as tool of choice
in patients undergoing mastectomy as it significantly reduces
blood loss. Its impact on the incidence of breast seroma is still
under scrutiny. Our results failed to show any statistically signif-
icant difference (p value = 0.275) in the incidence of breast seroma
amongst the MD (36%) and the ABC (30%) group. ABC is more
costly than the standard MD and their use need to be carefully
considered in an era of over-stretched NHS financial budget.
The need for further randomized studies is unquestionable.
doi:10.1016/j.ejcsup.2010.06.062
O-62 ONCOPLASTIC SURGERY: WHO IS DOING WHAT?
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Oncoplastic breast surgery combines plastic surgery tech-
niques and breast cancer resection to improve cosmesis. Does
its high profile reflect current practice?
Aims: Which oncoplastic procedures are being provided by
whom? What are their concerns, do they agree with guidelines?
Methods: A questionnaire was distributed to members of the
Association of Breast Surgery and BAPRAS.
Results: Two hundred and twenty eight surgeons responded (70
plastics (P), 158 breast (B)) of whom 41% thought oncoplastic sur-
gery should be universally available.
Ipsilateral procedures were usually performed by general sur-
geons with oncoplastic training (90) or in a combined case (68).
Breast surgeons were more likely to use rearrangement tech-
niques (therapeutic mammaplasty (33%P, 40%B), Grisotti flaps
(17%P, 27%B)) than plastic surgeons, who were more likely to
use reconstructive procedures (LD flap (79%P, 52%B), tissue
expanders (73%P, 47%B)). Therapeutic mammaplasty was felt to
be under-utilized.
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